What changed between these versions
A complete substitute amendment. While v1 focused on prohibiting acts related to counterfeit fentanyl and methamphetamine substances, v2 fundamentally shifts the bill's primary focus to regulating tableting and encapsulating machines and their critical parts to prevent illicit drug manufacturing. v2 also redefines and expands provisions related to counterfeit pills containing illicit synthetic substances, incorporating some themes from v1 but within a new, broader framework.
Overview
Extensive changes throughout the bill, fundamentally altering its primary focus and introducing a new regulatory framework. · v2 fundamentally restructures the bill's purpose, shifting its primary focus to regulating drug manufacturing equipment while simultaneously expanding and refining its approach to counterfeit substances.
v2 represents a fundamental restructuring of H.R. 8005, pivoting its primary legislative intent from directly addressing counterfeit fentanyl and methamphetamine substances to establishing a comprehensive regulatory framework for tableting and encapsulating machines used in illicit drug manufacturing. This includes new definitions, record-keeping requirements, prohibited acts, and extraterritorial jurisdiction related to these machines. Additionally, v2 redefines and broadens the scope of "counterfeit pills containing an illicit synthetic substance," incorporating and expanding upon some of the enforcement, education, and reporting mechanisms originally proposed in v1, but under a more expansive definition.
Major additions
This section adds several new definitions to Section 102 of the Controlled Substances Act (21 U.S.C. 802), including "critical part" (specifying upper punch, lower punch, die, and other Attorney General-determined parts), "die," "lower punch," "punch," and "upper punch." It also modifies existing definitions of "regulated person," "regulated transaction," and related terms to explicitly include tableting machines, encapsulating machines, and their critical parts.
These additions establish the foundational terminology for regulating drug manufacturing equipment, bringing manufacturers, distributors, and traders of these machines and their components under the purview of the Controlled Substances Act. This significantly expands the scope of federal oversight in preventing illicit drug production.
This section amends Section 310 of the Controlled Substances Act (21 U.S.C. 830) to require records of regulated transactions and reports to the Attorney General for tableting machines, encapsulating machines, and their critical parts. It mandates that these machines and parts be identified by permanently affixed serial numbers and requires the Attorney General to promulgate regulations for these requirements, including for machines manufactured before enactment.
This creates a new compliance burden for entities involved with these machines, requiring detailed record-keeping and reporting to federal authorities. The serial number requirement aims to enhance traceability and accountability, making it more difficult for illicit manufacturers to acquire and use such equipment undetected. The mandate for regulations ensures timely implementation.
This section amends Section 403(a) of the Controlled Substances Act (21 U.S.C. 843(a)) by adding two new prohibited acts: (10) removing, altering, or obliterating any required serial number on a tableting machine, encapsulating machine, or critical part; and (11) transporting, shipping, receiving, possessing, distributing, delivering, selling, importing, or exporting such a machine or part knowing its serial number has been removed, altered, or obliterated.
These additions create new criminal offenses specifically targeting the tampering with or trafficking of drug manufacturing equipment with altered identification. This directly aims to disrupt illicit manufacturing supply chains by penalizing actions that facilitate the clandestine use of these machines.
This section amends Sections 1009 and 1010 of the Controlled Substances Act (21 U.S.C. 959 and 960) to establish extraterritorial jurisdiction. It makes it unlawful to manufacture or distribute tableting machines, encapsulating machines, or critical parts with the intent or knowledge that they will be used to illicitly manufacture controlled substances or listed chemicals, and with the intent, knowledge, or reasonable cause to believe they will be unlawfully imported into the United States. It also establishes specific imprisonment periods for these violations and directs the United States Sentencing Commission to review and amend federal sentencing guidelines.
This significantly expands the reach of U.S. law enforcement to target the international supply chain of illicit drug manufacturing equipment. It provides a legal basis to prosecute individuals and entities operating outside U.S. borders who facilitate the illicit production and importation of drugs into the country, and increases the penalties for such actions.
This section introduces a new definition for "counterfeit pill containing an illicit synthetic substance." This term refers to a substance in pill or tablet form that is a counterfeit substance (as defined in 21 U.S.C. 802(7)) and contains fentanyl, an analogue of fentanyl, a fentanyl-related substance, methamphetamine, an illicit depressant or stimulant substance, an illicit narcotic, or an illicit synthetic opioid.
This new definition broadens the scope of substances covered by the bill's provisions related to counterfeit pills. While v1 focused specifically on 'counterfeit fentanyl or methamphetamine substances,' v2's definition encompasses a wider array of illicit synthetic substances, allowing for more comprehensive enforcement and prevention efforts against a broader range of dangerous counterfeit pills.
This new clause adds a specific requirement to the annual report to Congress, mandating "A description of pharmaceutical markings used for counterfeit pills containing an illicit synthetic substance, including how the markings compare to required labeling for products approved by the Food and Drug Administration."
This addition provides Congress with crucial intelligence on the methods used by illicit manufacturers to mimic legitimate pharmaceuticals. This information can inform public awareness campaigns, law enforcement training, and regulatory responses to better identify and combat counterfeit pills.
Deletions
This section defined "counterfeit fentanyl or methamphetamine substance" as a substance containing fentanyl, any analogue of fentanyl, or methamphetamine, and falsely bearing the trademark or identifying mark of another product.
The specific definition of "counterfeit fentanyl or methamphetamine substance" is removed. While v2 introduces a new, broader definition of "counterfeit pill containing an illicit synthetic substance" in Section 4(a), the precise scope and terminology of v1's definition are no longer operative. This deletion, coupled with the new definition, indicates a shift towards a more expansive approach to counterfeit pills beyond just fentanyl and methamphetamine, but also potentially a more specific focus on 'pills' rather than 'substances' generally in this context.
This section required the Administrator of the Drug Enforcement Administration to establish and implement an operation and response plan specifically to address "counterfeit fentanyl or methamphetamine substances." The plan included strategies for federal law enforcement, increased education and prevention efforts (tailored to youth), and an audit of current campaigns like "One Pill Can Kill."
The specific comprehensive plan targeting "counterfeit fentanyl or methamphetamine substances" is deleted. While v2 introduces a similar plan in Section 4(c), it is directed at the broader category of "counterfeit pills containing an illicit synthetic substance." This deletion signifies a shift from a narrowly defined target to a more expansive one for DEA's operational planning and resource allocation, effectively replacing the original plan with a modified, broader version.
This section mandated annual reports from the Attorney General, in consultation with the DEA Administrator and ONDCP Director, on information regarding the collection and prosecutions of "counterfeit fentanyl or methamphetamine substances." The report's contents included data on aggregate seizures, breakdown of substances in pill form, seizure locations/times, charges/convictions under 21 U.S.C. 841(a) (particularly for pill form), and prevention measures.
The specific annual reporting requirement focused solely on "counterfeit fentanyl or methamphetamine substances" is deleted. Similar to the comprehensive plan, v2 introduces a modified reporting requirement in Section 4(d) that targets the broader "counterfeit pills containing an illicit synthetic substance" and includes additional details (like pharmaceutical markings) and a sunset clause. This deletion, therefore, represents a shift to a more comprehensive and time-limited reporting framework for counterfeit pills, rather than a complete abandonment of reporting.
Modifications
The legislative intent and the primary subject matter of the bill are entirely reoriented, signaling a fundamental shift in focus for federal drug enforcement and regulatory efforts from directly addressing counterfeit substances to controlling the tools used in their illicit manufacture.
Before
The bill's title stated its purpose was to amend the Controlled Substances Act to prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances, and for other purposes.
After
The bill's title states its purpose is to amend the Controlled Substances Act to prevent the misuse of a tableting machine, encapsulating machine, or critical part of a tableting and encapsulating machine for the illicit manufacture of a controlled substance or listed chemical, and for other purposes.
This change narrows the scope of the prohibited act in this specific amendment. While v1's language covered any "counterfeit substance" in this context, v2 specifically targets "fentanyl-related substances." This could potentially limit the application of this specific prohibition to a more defined category of substances, depending on the interpretation and definition of "fentanyl-related substance" within the broader Controlled Substances Act.
Before
v1 amended Section 403(d)(2) of the Controlled Substances Act (21 U.S.C. 843(d)(2)) by inserting ", fentanyl, an analogue of fentanyl, or a counterfeit substance" after "methamphetamine" in the matter preceding subparagraph (A).
After
v2 amends Section 403(d)(2) of the Controlled Substances Act (21 U.S.C. 843(d)(2)) by inserting ", fentanyl, an analogue of fentanyl, or a fentanyl-related substance" after "methamphetamine" in the matter preceding subparagraph (A).
The DEA's operational and response plan is now directed at a wider array of illicit substances found in counterfeit pills, potentially expanding the scope of their efforts and resource allocation to include illicit depressants, stimulants, narcotics, and synthetic opioids beyond just fentanyl and methamphetamine. This aims for a more holistic approach to the counterfeit pill crisis.
Before
v1 required the DEA Administrator to establish a comprehensive plan to address "counterfeit fentanyl or methamphetamine substances," including strategies for law enforcement, increased education and prevention efforts (tailored to youth), and an audit of current campaigns like "One Pill Can Kill."
After
v2 requires the DEA Administrator to establish a comprehensive plan to address "counterfeit pills containing an illicit synthetic substance," with similar content requirements for law enforcement strategies, education and prevention efforts (including Operation Engage and tailoring to youth/teen access), and an audit of current campaigns.
The reporting requirements are expanded to cover a broader range of illicit substances in counterfeit pills, providing Congress with more comprehensive data on the issue. The addition of a sunset clause introduces a time limit to this reporting obligation. The new focus on pharmaceutical markings provides novel intelligence into the counterfeiting process, aiding in identification and public awareness.
Before
v1 required annual reports from the Attorney General on "counterfeit fentanyl or methamphetamine substances," including data on aggregate seizures, breakdown of substances in pill form, illicit substances present, seizure locations/times, charges/convictions under 21 U.S.C. 841(a) (particularly for pill form), and prevention measures.
After
v2 requires annual reports (through fiscal year 2031) from the Attorney General on "counterfeit pills containing an illicit synthetic substance," including data on aggregate seizures, a description of pharmaceutical markings, a breakdown of illicit substances, geographic origin/seizure points, charges/convictions under 21 U.S.C. 841(a), and prevention measures.
Scope
Fundamental restructuring — Changes are scattered throughout the bill, introducing entirely new sections on machine regulation while also modifying and expanding existing themes related to counterfeit substances. — v2 represents a significant change in policy direction, shifting the primary focus from direct prohibition and enforcement against specific counterfeit substances to a preventative regulatory approach targeting the manufacturing tools, while simultaneously broadening the scope of counterfeit substance enforcement. — The changes extensively amend and add to existing sections of the Controlled Substances Act (21 U.S.C. 802, 830, 843, 959, 960), creating new definitions, regulatory requirements, prohibited acts, and extraterritorial jurisdiction that interact broadly with the existing legal framework for controlled substances and listed chemicals.
Impact analysis
Manufacturers, distributors, importers, exporters, brokers, and traders of tableting and encapsulating machines and their critical parts
New regulatory burdens and increased legal liability.
These entities are now explicitly designated as "regulated persons" under the Controlled Substances Act. They face new requirements for record-keeping, reporting transactions (including serial numbers), and are subject to new prohibited acts related to serial number alteration or trafficking of altered machines.
Individuals and organizations involved in the illicit manufacture of controlled substances or listed chemicals
Increased barriers to illicit activity and heightened legal risk.
These individuals face increased difficulty in acquiring and using tableting and encapsulating machines due to new regulations, serial number requirements, and prohibitions on altering or trafficking altered machines. They are also subject to new extraterritorial jurisdiction provisions if involved in manufacturing or distributing these machines for unlawful importation into the U.S.
Federal law enforcement agencies, particularly the Drug Enforcement Administration (DEA) and Department of Justice (DOJ)
Expanded authority and responsibilities.
These agencies gain new tools and authorities to investigate and prosecute illicit manufacturing operations by regulating the equipment used. Their comprehensive plan and reporting duties are expanded to cover a broader range of "counterfeit pills containing an illicit synthetic substance."
Individuals involved in the production or distribution of counterfeit pills containing a wider array of illicit synthetic substances
Increased legal liability due to broader definitions and continued enforcement focus.
The definition of the substances they deal with is broadened from specific fentanyl/methamphetamine substances to a wider range of "illicit synthetic substances" in pill form, potentially increasing the scope of applicable prohibitions and enforcement actions.
Congress and policymakers
Improved information for decision-making, with a time limit on data collection.
Will receive more detailed and broader annual reports on counterfeit pills, including new information on pharmaceutical markings, but these reports will sunset after fiscal year 2031.